Article
Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.
British journal of cancer - 26 Feb 2008
Mellemkjaer L, Dahl C, Olsen J H, Bertelsen L, Guldberg P, Christensen J, Børresen-Dale A-L, Stovall M, Langholz B, Bernstein L, Lynch C F, Malone K E, Haile R W, Andersson M, Thomas D C, Concannon P, Capanu M, Boice J D, Bernstein J L
Abstract excerpt
The protein encoded by the CHEK2 gene is involved in cellular repair of DNA damage. The truncating mutation, CHEK2*1100delC, seems to increase the risk for breast cancer. We investigated whether the CHEK2*1100delC mutation carrier status increases the risk for asynchronous contralateral breast cancer (CBC) and whether it interacts with radiation therapy (RT) or chemotherapy in regard to CBC risk. The germline...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.